1:
Patient characteristics before and after propensity score matching.
| Study cohort without propensity score matching | Patients matched by propensity score | ||||||
|---|---|---|---|---|---|---|---|
| All patients, n=169 | Chemo-group, n=121 |
HSCT group, n=48 (%) |
p | Chemo-group, n=41 |
HSCT group, n=41 |
p | |
| Median age diagnosis (median, IQR) | 59 (50–68) | 62 (52–70) | 55 (47–62) | 0.002 | 56 (49–65) | 56 (52–62) | 0.48 |
| WBC at diagnosis (median, IQR) | 11.6 (3.8–29.7) | 12 (4–28.2) | 9 (3.1–36.75) | 0.99 | 9.8 (4.9–19.4) | 11.3 (4.2–51.4) | 0.24 |
| Platelet count at diagnosis (median, IQR) | 45 (25–74) | 45 (25–71) | 45 (22.5–83) | 0.99 | 43 (30–79) | 52 (31–91) | 0.73 |
| BM blast at diagnosis (median, IQR) | 43 (12–74) | 46 (13–75) | 32.5 (6.5–63.5) | 0.18 | 58 (28–82) | 32 (7–64) | 0.07 |
| Cytogenetics at diagnosis | 164/169 | 119/121 | 45/48 | ||||
| Diploid | 128 (78%) | 95 (79.8%) | 33 (73.3%) | 34(85%) | 29(74.4%) | ||
| Other | 36 (22%) | 24 (20.2%) | 12 (26.7%) | 0.40 | 6(15%) | 10(25.6%) | 0.13 |
| No of FLT3-ITD mutations at diagnosis | 163/169 | 116/121 | 47/48 | ||||
| 1 | 130 (79.8%) | 95 (81.9%) | 35 (74.5%) | 33(80.5%) | 31(75.6%) | ||
| >1 | 33 (20.2%) | 21 (18.1%) | 12 (25.5%) | 0.29 | 8(19.5%) | 10(24.4%) | 0.56 |
| FLT3-ITD allelic ratio at diagnosis(median, IQR) | 0.34 (0.11–0.48) | 0.35 (0.12–0.49) | 0.3 (0.04–0.48) | 0.29 | 0.18 (0.04–0.45) | 0.32 (0.05–0.48) | 0.46 |
| FLT3-ITD allelic ration ≥0.3 at diagnosis | 163/169 | 116/121 | 47/48 | ||||
| Yes | 88 (54%) | 65 (56%) | 23 (48.9%) | 19(46.3%) | 22(53.7%) | ||
| No | 75 (46%) | 51 (44%) | 24 (51.1%) | 0.49 | 22(53.7%) | 19(46.3%) | 0.44 |
| FLT3-ITD allelic ration ≥0.5 at diagnosis | 163/169 | 116/121 | 47/48 | ||||
| Yes | 37 (22.7%) | 29 (25%) | 8 (17%) | 9(22%) | 7(17.1%) | ||
| No | 126 (77.3%) | 87 (75%) | 39 (83%) | 0.31 | 32(78%) | 34(82.9%) | 0.62 |
| Presence of NPM1 mutation | |||||||
| Yes | 56 (33.1%) | 37 (30.6%) | 19 (39.6%) | 18(43.9%) | 17(41.5%) | ||
| No | 57 (33.7%) | 42 (34.7%) | 15 (31.3%) | 12(29.3%) | 14(34.1%) | ||
| Unknown | 56 (33.1%) | 42 (34.7%) | 14 (29.2%) | 0.55 | 11(26.8%) | 10(24.4%) | 0.85 |
| Use of FLT3 inhibitors as induction/consolidation | |||||||
| Yes | 37 (21.9%) | 27 (22.3%) | 10 (20.8%) | 10(24.4%) | 8(19.5%) | ||
| No | 132 (78.2%) | 94 (77.7%) | 38 (79.2%) | 1.0 | 31(75.6%) | 33(80.5%) | 0.53 |
| Year of diagnosis after 2008 | |||||||
| Yes | 106 (62.7%) | 68 (56.2%) | 38 (79.2%) | 31(75.6%) | 31(75.6%) | ||
| No | 63 (37.3%) | 53 (43.8%) | 10 (20.8%) | 0.01 | 10(24.4%) | 10(24.4%) | 1.00 |
| Use of high dose cytarabine regimen before HCT | |||||||
| Yes | 113(66.9%) | 71(58.7%) | 42(87.5%) | 34(82.9%) | 35(85.4%) | ||
| No | 56(33.1%) | 50(41.3%) | 6(12.5%) | <0.001 | 7(17.1%) | 6(14.6%) | 0.65 |
| ECOG performance status at diagnosis | 155/169 | 110/121 | 45/48 | 36/41 | 38/41 | ||
| 0–1 | 134 (86.5%) | 92 (83.6%) | 42 (93.3%) | 31(86.1%) | 36(94.7%) | ||
| 2–3 | 55 (13.5%) | 18 (16.4%) | 3 (6.7%) | 0.1 | 5 (13.9%) | 2 (5.3%) | 0.2 |
Abbreviations: HSCT, hematopoietic stem cell transplantation; IQR, interquartile range; BM, bone marrow.